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Abstract In-hospital bleeding (IHB) is associated with
the risk of subsequent cardiovascular events (CVE) in
acute coronary syndrome (ACS). We investigated whether
increased risk of CVE by IHB is influenced by chronic
kidney disease (CKD) or both have detrimental effects on
CVE. In a Taiwan national-wide registry, 2819 ACS
patients were enrolled. CKD is defined as an estimated
glomerular filtration rate of\60 ml/min per 1.73 m2. The
primary end point is the composite of death, non-fatal
myocardial infarction and non-fatal stroke at 12 months. 53
(1.88 %) and 949 (33.7 %) patients suffered from IHB and
CKD, respectively. Both IHB and CKD are independently
associated with increased risk of the primary end point (HR
2.04, 95 % CI 1.05–3.99, p = 0.037 and HR 2.17, 95 % CI
1.63–2.87, p\ 0.01, respectively). The Kaplan–Meier
curves show significantly higher event rates among those
with IHB and CKD in the whole, ST-elevation and non-ST
elevation populations (all p\ 0.01). Patients with IHB(?)/
CKD(-), IHB(-)/CKD(?) and IHB(?)/CKD(?) have
1.88-, 2.13- and 2.98-fold risk to suffer from the primary
end point compared with those without IHB and CKD
(p = 0.23,\0.01 and\0.01, respectively). IHB or CKD is
independently associated with poor cardiovascular out-
come and patients with both IHB and CKD have the worst
outcome in ACS.




ACS Acute coronary syndrome
CVE Cardiovascular events
PCI Percutaneous coronary intervention
CKD Chronic kidney disease
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IHB In-hospital bleeding
TIMI Thrombolysis in myocardial infarction
MI Myocardial infarction
GFR Glomerular filtration rate
ESRD End-stage renal disease
MDRD Modification of diet in renal disease
STE-ACS ST-elevation acute coronary syndrome
DBP Diastolic blood pressure
CAD Coronary artery disease
CVA Cerebrovascular accident
NSTE-ACS Non-ST-elevation acute coronary syndrome
Introduction
Cardiovascular disease (CVD) accounts for approximately
one-third of all global deaths [1]. The prevalence of CVD
has increased considerably in Asian countries over the past
several decades as a result of shifts toward a more
‘‘westernized’’ lifestyle. In Taiwan, CVD is the second
most common cause of mortality since 2010 [2]. Acute
coronary syndrome (ACS) is the most severe form of CVD.
Because of its major impact on morbidity and mortality, as
well as its contribution to annual health-care costs, it is of
the utmost importance to develop improved strategies for
reducing cardiovascular events (CVE) and preventing
complications.
In ACS, aggressive antiplatelet and anticoagulation
therapies have been recently developed and can reduce
future CVE, but may increase the risk of bleeding. Anemia
and bleeding events have been shown to increase mortality
in studies of ACS and percutaneous coronary intervention
(PCI) [3, 4]. Because lower body weight could be associ-
ated with bleeding complication in ACS, weight-adjusted
dose of antithrombotic agent is recommended in the
international ACS guidelines [5, 6]. Compared with Cau-
casians, the Asian population usually has lower body
weight and might possibly suffer from antithrombotic and
antiplatelet overdose. Although bleeding events increase
the risk of mortality in the Caucasian population, no study
has been reported in the Asian population.
Chronic kidney disease (CKD) is a risk factor for cor-
onary heart disease and bleeding with antithrombotic
therapy in patients with ACS [7, 8]. Whether the associa-
tion between bleeding and mortality is influenced by the
presence of CKD or both have independently detrimental
effects on CVE is unknown. In this study, we test the
hypothesis that in-hospital bleeding (IHB), using Throm-
bolysis in Myocardial Infarction (TIMI) bleeding defini-
tion, would increase the risk of CVE, and CKD might have
an additively detrimental effect on CVE in a prospective
cohort in an Asia endemic area of kidney disease [9].
Patients and methods
Study design
The study was a prospective, national, multicenter, non-
interventional, observational design. Patient recruitment
and definition of ACS had been previously described in
detail [10]. In brief, patients who were aged 20 years or
older, who were admitted within 24 h to the hospital with
symptoms of ACS and who provided informed consent
were eligible to be included in the study. Patient data, such
as baseline characteristics, risk factors, clinical presenta-
tion, clinical diagnosis, in-hospital interventions as well as
medications prescribed were collected from admission to
discharge. Patients were followed up at months 3, 6, 9 and
12 post-discharge and data were collected on medication
usage, revascularization strategy as well as clinical events,
such as death, myocardial infarction (MI), stroke, revas-
cularization and hospitalization. Monitoring for source
documentation and accuracy was performed in 5 % of all
case report forms at each recruiting site. This study was
carried out in accordance with the local regulatory guide-
lines and international guidelines for Good Epidemiologi-
cal Practice [11]. Ethics committee approval was obtained
at all trial sites. Written informed consent was given by the
patients for their information to be stored in the hospital
database and used for research.
Thrombolysis in Myocardial Infarction (TIMI) bleeding
classification
TIMI bleeding classification includes major and minor
bleeding. TIMI major bleeding is defined as patients with
intracranial hemorrhage or a C5 g/dl decrease in hemo-
globin concentration or a C15 % absolute decrease in
hematocrit. If observed with blood loss C3 g/dl, decrease
in hemoglobin concentration or C10 % decrease in
hematocrit, or no observed blood loss with C4 g/dl
decrease in hemoglobin concentration or C12 % decrease
in hematocrit, it is defined as TIMI minor bleeding [12].
Calculation of kidney function and definition of CKD
The estimated glomerular filtration rate (GFR) was calcu-
lated using the Modification of Diet in Renal Disease
(MDRD) Study equation [GFR = 186.3 9 (serum creati-
nine in mg/dl)-1.154 9 (age)-0.203 9 (0.742 if female)]
[13]. Chronic kidney disease was defined as a GFR
\60 ml/min per 1.73 m2. This range corresponds to stage
3 or higher CKD by the National Kidney Foundation’s
classification scheme and helps identify individuals with
clinically significant CKD [14].
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Statistical analysis
The sample size for the Taiwan ACS Full Spectrum Registry
was calculated as follows. There are about 50000 new ACS
cases per year in Taiwan. Based on a known background
incidence rate of 0.0025, a sample of 2395 patients would
achieve 80 % power to detect an additional incidence rate of
0.003 with a precision of 0.2 % and 95 % confidence inter-
val. Taking into account a dropout rate of 20 %, a sample of
3000 was considered to be adequately representative.
All data were expressed as mean ± standard deviation
(SD). For comparability between groups, a Chi-square test
or Fisher’s exact test was used for categorical variables and
one-way analysis of variance (ANOVA) was adopted for
continuous variables. One-year CVE analysis was per-
formed using Kaplan–Meier survival curves and the log-
rank test. Univariate and multivariate logistic regression
analyses were conducted to analyze odds ratio (OR) and
Cox regression model was used for hazard ratio (HR)
calculation for IHB or CVE. The adjusted variables in
model 1 include age and sex. The adjusted variables in
model 2 include model 1 covariates and medicine at dis-
charge (aspirin, clopidogrel, angiotensin-converting
enzyme inhibitor, angiotensin II receptor blocker, beta-
blocker and statin). Analyses were conducted as time to
first event without double counting of events within anal-
yses involving composite end points.
The primary outcome was the composite CVE of death,
non-fatal myocardial infarction and non-fatal stroke at
1 year. The secondary outcome was the CVE of death,
non-fatal myocardial infarction, non-fatal stroke, re-hos-
pitalization and revascularization at 1 year. We analyzed
the whole, STE-ACS and NSTE-ACS populations sepa-
rately. Statistical analysis was performed using SAS soft-
ware version 9.2 (SAS Institute Inc., Cary, NC, USA). All
statistical analyses were performed using a level of\0.05




A total of 3183 eligible consecutive patients were enrolled
between October 2008 and January 2010 at 39 medical
centers and regional hospitals in Taiwan. Among them,
2819 (88.6 %) subjects with renal parameters and
12 months outcome data were analyzed in this study and
1537 (54.5 %) patients had ST-segment elevation acute
coronary syndrome (STE-ACS). The subjects included
2230 men and 589 women (male 79.11 %). Mean age was
62.9 ± 13.5 years.
Overall, 53 (1.88 %) patients had TIMI bleeding
including 17 (0.60 %) major and 36 (1.28 %) minor. The
TIMI major bleeding included 1 intracranial hemorrhage, 1
coronary artery bypass grafting (CABG)-related bleeding,
8 gastrointestinal (GI) bleeding, 3 genitourinary (GU)
bleeding and 5 other location bleeding. The TIMI minor
bleeding included 2 vascular access sites bleeding, 5
CABG-related bleeding, 23 GI bleeding, 1 GU bleeding
and 4 other location bleeding. Compared with no TIMI
bleeding subjects, those with TIMI bleeding were older and
thinner, had higher grade of Killip class, lower systolic and
diastolic blood pressure (DBP) and MDRD GFR at pre-
sentation, and lower percentage of cerebrovascular acci-
dent (CVA) (Table 1).
Baseline creatininewas 3.0 ± 2.6 and 1.0 ± 0.2 mg/dl in
the CKD (n = 949) and non-CKD (n = 1870) groups.
Compared with non-CKD subjects, those with CKD were
older, shorter and thinner, includedmore women, had higher
grade of Killip class, lower DBP and faster heart rate at
presentation. They also had more comorbidity including
hypertension, diabetes, previous coronary artery disease
(CAD), previous CVA and previous heart failure, but lower
percentage of smoking and family history of CAD.
Pharmacological management during admission
Medications prescribed during admission are shown in
Table 1. Aspirin, clopidogrel, b-blocker, statins and un-
fractional heparin were prescribed less often during
admission in patients with than those without TIMI
bleeding. Glycoprotein IIb/IIa was prescribed more often to
TIMI bleeding patients during admission. There was no
significant difference regarding use of low molecular
weight heparin, warfarin, ticlopidine and renin angiotensin
system blockers between two group.
Binary regression analysis found age [OR 1.03, 95 %
confidence interval (CI) 1.01–1.06, p = 0.015], Killip class
(p\ 0.01), use of glycoprotein IIb/IIIa (OR 2.49, 95 % CI
1.27–4.88, p\ 0.01) and unfractional heparin (OR 0.36,
95 % CI 0.19–0.68, p\ 0.01) to be independent predictors
for occurrence of IHB (Table 2).
Cardiovascular outcomes
During admission patients with TIMI bleeding had more
death and stroke (8.77 vs 1.50 % and 3.51 vs 0.36 %, both
p\ 0.01), but similar recurrent myocardial infarction (1.75
vs 0.75 %, p = 0.388) compared with no TIMI bleeding
subjects (Table 3). Those with TIMI bleeding still had
more death rate at 3, 6, 9 and 12 months follow-up (all
p\ 0.01). The re-hospitalization rate was higher during the
3 and 6 months follow-up in those suffering from TIMI
bleeding (both p\ 0.01).
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Sex (male) 38 (71.70 %) 2192 (79.25 %) 0.181 1530 (82.88 %) 21 (87.50 %) 662 (71.96 %) 17 (58.62 %) \0.01
Age (year) 68.29 ± 13.83 62.77 ± 13.51 \0.01 59.45 ± 13.03 63.30 ± 15.69 69.43 ± 11.93 72.42 ± 10.69 \0.01
Killip
Class 1 12 (26.67 %) 1394 (62.20 %) \0.01 1053 (69.23 %) 6 (31.58 %) 341 (47.36 %) 6 (23.08 %) \0.01
Class 2 8 (17.78 %) 394 (17.58 %) 262 (17.23 %) 5 (26.32 %) 132 (18.33 %) 3 (11.54 %)
Class 3 7 (15.56 %) 238 (10.62 %) 111 (7.30 %) 2 (10.53 %) 127 (17.64 %) 5 (19.23 %)
Class 4 18 (40.00 %) 215 (9.59 %) 95 (6.25 %) 6 (31.58 %) 120 (16.67 %) 12 (46.15 %)
Blood pressure
SBP (mmHg) 126.39 ± 35.66 139.57 ± 32.63 \0.01 139.64 ± 30.47 126.38 ± 32.98 139.44 ± 36.63 126.41 ± 38.51 0.043
DBP (mmHg) 76.06 ± 21.67 82.10 ± 20.82 0.040 83.63 ± 19.73 73.08 ± 16.82 79.04 ± 22.55 78.70 ± 25.25 \0.01
Heart rate (beat/
min)
85.33 ± 30.80 82.03 ± 22.13 0.292 79.79 ± 19.66 84.29 ± 29.36 86.54 ± 25.84 86.21 ± 32.50 \0.01
Height (cm) 162.13 ± 7.93 164.03 ± 7.87 0.082 164.60 ± 7.67 164.67 ± 6.08 162.90 ± 8.15 160.03 ± 8.73 \0.01
Weight (kg) 63.98 ± 12.60 68.70 ± 12.81 \0.01 69.92 ± 12.81 66.27 ± 13.16 66.26 ± 12.47 62.09 ± 12.01 \0.01
Waist
circumference
86.47 ± 11.61 90.53 ± 9.51 0.084 90.68 ± 9.23 83.67 ± 13.41 90.19 ± 10.13 88.00 ± 10.88 0.241
Creatinine (mg/
dl)
1.73 ± 1.43 1.64 ± 1.82 0.730 0.96 ± 0.19 1.07 ± 0.16 3.01 ± 2.65 2.27 ± 1.76 \0.01
MDRD eGFR 56.05 ± 23.92 73.62 ± 50.90 0.012 92.30 ± 51.68 77.66 ± 11.75 36.14 ± 18.00 38.17 ± 14.77 \0.01
Dyslipidemia 20 (37.74 %) 1073 (39.13 %) 0.837 708 (38.69 %) 9 (37.50 %) 365 (40.02 %) 11 (37.93 %) 0.919
Hypertension 35 (66.04 %) 1741 (63.52 %) 0.706 1040 (56.83 %) 13 (54.17 %) 701 (76.95 %) 22 (75.86 %) \0.01
Diabetes 24 (45.28 %) 988 (35.91 %) 0.160 505 (27.49 %) 8 (33.33 %) 483 (52.84 %) 16 (55.17 %) \0.01
Smoker
Current 22 (41.51 %) 1161 (42.72 %) 0.916 899 (49.48 %) 15 (62.50 %) 262 (29.08 %) 7 (24.14 %) \0.01
Former 10 (18.87 %) 454 (16.70 %) 264 (14.53 %) 3 (12.50 %) 190 (21.09 %) 7 (24.14 %)




7 (16.67 %) 478 (22.58 %) 0.363 378 (25.93 %) 5 (27.78 %) 100 (15.17 %) 2 (8.33 %) \0.01
Previous CAD 12 (22.64 %) 663 (23.97 %) 0.822 354 (19.18 %) 4 (16.67 %) 309 (33.59 %) 8 (27.59 %) \0.01
Previous heart
failure
4 (7.55 %) 144 (5.21 %) 0.449 53 (2.87 %) 1 (4.17 %) 91 (9.89 %) 3 (10.34 %) \0.01
Old CVA 0 (0.00 %) 252 (9.11 %) 0.021 118 (6.39 %) 0 (0.00 %) 134 (14.57 %) 0 (0.00 %) \0.01
In-hospital medication
Aspirin 44 (83.02 %) 2551 (92.23 %) 0.014 1738 (94.15 %) 19 (79.17 %) 813 (88.37 %) 25 (86.21 %) \0.01
Clopidogrel 46 (86.79 %) 2614 (94.50 %) 0.016 1769 (95.83 %) 21 (87.50 %) 845 (91.85 %) 25 (86.21 %) \0.01
Ticlopidine 0 (0.00 %) 21 (0.76 %) 0.524 13 (0.70 %) 0 (0.00 %) 8 (0.87 %) 0 (0.00 %) 0.889
Warfarin 0 (0.00 %) 27 (0.98 %) 0.470 14 (0.76 %) 0 (0.00 %) 13 (1.41 %) 0 (0.00 %) 0.348
Glycoprotein
IIb/IIIa
17 (32.08 %) 457 (16.52 %) \0.01 317 (17.17 %) 9 (37.50 %) 140 (15.22 %) 8 (27.59 %) \0.01
Unfractional
heparin
29 (54.72 %) 2024 (73.17 %) \0.01 1361 (73.73 %) 13 (54.17 %) 663 (72.07 %) 16 (55.17 %) 0.020
LMWH 16 (30.19 %) 816 (29.50 %) 0.913 559 (30.28 %) 9 (37.50 %) 257 (27.93 %) 7 (24.14 %) 0.429
ACEI 24 (45.28 %) 1392 (50.33 %) 0.467 1005 (54.44 %) 10 (41.67 %) 387 (42.07 %) 14 (48.28 %) \0.01
ARB 5 (9.43 %) 316 (11.42 %) 0.651 178 (9.64 %) 1 (4.17 %) 138 (15.00 %) 4 (13.79 %) \0.01
b-blocker 15 (28.30 %) 1268 (45.84 %) 0.011 873 (47.29 %) 8 (33.33 %) 395 (42.93 %) 7 (24.14 %) \0.01
Statin 18 (33.96 %) 1367 (49.42 %) 0.026 953 (51.63 %) 9 (37.50 %) 414 (45.00 %) 9 (31.03 %) \0.01
TIMI thrombolysis in myocardial infarction, SBP systolic blood pressure, DBP diastolic blood pressure, MDRD Modification of Diet in Renal Disease
Study, eGFR estimated glomerular filtration rate, FH family history, CAD coronary artery disease, CVA cerebrovascular accident, LMWH low molecular
weight heparin, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker
444 Heart Vessels (2015) 30:441–450
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The unadjustedHRof the presence ofTIMI bleeding in the
whole, STE-ACS and non-ST-segment elevation ACS
(NSTE-ACS) populations were 3.66 (95 % CI 2.18–6.1),
2.88 (95 % CI 1.35–6.18) and 5.36 (95 % CI 2.62–10.95),
respectively, for the primary end point. For the secondary end
point the HR of the presence of TIMI bleeding in the whole,
STE-ACS and NSTE-ACS populations were1.74 (95 % CI
1.19–2.53), 1.35 (95 % CI 0.81–2.25) and 2.58 (95 % CI
1.49–4.49), respectively. The association was statistically
significant after adjusting for age, sex and medication at
discharge in the NSTE-ACS population for the primary
outcomes (HR 2.74, 95 %CI 1.29–5.84, p\ 0.01), but not in
the STE-ACS population. For the secondary outcome, TIMI
bleeding is still a predictor only in theNSTE-ACS population
after adjusting for age, sex and medication at discharge (HR
1.95, 95 % CI 1.10–3.45, p = 0.022). There is a trend for in-
hospital bleeding being a predictor for the primary end point
in those with NSTE-ACS after adjusting for age, sex, medi-
cation at discharge, creatinine, weight and Killip class (HR
2.34, 95 % CI 0.94–5.86, p = 0.068) (Table 4).
Influence of TIMI bleeding and CKD on cardiovascular
outcome
CKD is independently associated with a significant
increase of primary end point after adjusting for age, sex
and medication at discharge (OR 2.17, 95 % CI 1.63–2.87,
p\ 0.01). The Kaplan–Meier curves show significantly
higher primary end point rates among those with IHB and
CKD in the whole, STE-ACS and NSTE-ACS populations
during 12 months follow-up (all p\ 0.01) (Fig. 1). We
found an additively detrimental effect on the CVE between
TIMI bleeding and CKD on the occurrence of primary end
point (Table 5). In patients without CKD, TIMI bleeding
had a 1.88-fold risk to have primary end point (HR 1.88,
95 % CI 0.68–5.21; p = 0.227). When patients had no
TIMI bleeding, presence of CKD was associated with a
2.13-fold risk of primary endpoint (HR 2.13, 95 % CI
1.62–2.79; p\ 0.01), but CKD patients with TIMI bleed-
ing had a 2.98-fold risk for primary endpoint (HR 2.98,
95 % CI 1.55–5.75; p\ 0.01), compared to the patients
without TIMI bleeding and CKD.
Discussion
There are three major findings in this ACS cohort study.
First, patients with IHB had higher risk of in-hospital and
12 months death. Second, IHB is associated with poor
cardiovascular outcome, especially in those in the NSTE-
ACS population. Third, patients with both IHB and CKD
had the worst prognosis during the 12 months follow-up.
Furthermore, they had additively detrimental effect on the
cardiovascular outcome.
By using TIMI bleeding definition our study found that
ACS patients with IHB had higher risk of in-hospital and
12 months death. Among the different bleeding definitions,
TIMI is more capable than ACUITY in identifying patients
with bleeding at higher risk for early mortality [15].
However, the other study suggests that bleeding assessed
with clinical criteria by Global Use of Strategies to Open
Occluded Coronary Arteries (GUSTO) bleeding criteria is
more important than that assessed by laboratory criteria
with TIMI bleeding criteria in terms of outcomes [16].
Recently, a consensus report from the Bleeding Academic
Research Consortium (BARC) proposed standardized
bleeding definitions through the use of a hierarchical
approach of describing bleeding severity grade in patients
Table 2 Predictors for in-





systolic blood pressure, DBP
diastolic blood pressure, MDRD
Modification of Diet in Renal
Disease Study, eGFR estimated
glomerular filtration rate
Unadjusted OR (95 % CI) p value Adjusted OR (95 % CI) p value
Age (year) 1.03 (1.01–1.05) \0.01 1.03 (1.01–1.06) 0.015
Killip IV 1 – 1
III 0.35 (0.14–0.86) 0.022 0.33 (0.13–0.83) 0.018
II 0.24 (0.10–0.57) \0.01 0.25 (0.11–0.60) \0.01
I 0.10 (0.05–0.22) \0.01 0.11 (0.05–0.24) \0.01
SBP 0.99 (0.98–1.00) \0.01
DBP 0.99 (0.97–1.00) 0.040
Weight (kg) 0.97 (0.95–0.99) \0.01
MDRD eGFR 0.98 (0.98–0.99) \0.01
Aspirin 0.41 (0.20–0.86) 0.017
Clopidogrel 0.38 (0.17–0.86) 0.020
Glycoprotein IIb/IIIa 2.39 (1.33–4.29) \0.01 2.49 (1.27–4.88) \0.01
Unfractional heparin 0.44 (0.26–0.77) \0.01 0.36 (0.19–0.68) \0.01
b-blocker 0.47 (0.26–0.85) 0.013
Statin 0.53 (0.30–0.93) 0.028
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receiving antithrombotic therapy [17]. One study had val-
idated a close association between bleeding events defined
according to BARC and 1-year mortality after PCI [18].
More studies might be needed to use BARC bleeding




index hospitalization, at 3, 6, 9






(n = 53) (%)
No TIMI bleeding
(n = 2766) (%)
All (n = 2819) (%) p value
In-hospital
Death 5 (8.77) 46 (1.50) 51 (1.63) \0.01
Re-infarction 1 (1.75) 23 (0.75) 24 (0.77) 0.388
Stroke 2 (3.51) 11 (0.36) 13 (0.42) \0.01
3-month follow-up
Death 8 (15.69) 84 (3.18) 92 (3.42) \0.01
Myocardial Infarction 2 (.44) 34 (1.31) 36 (1.37) 0.073
Stroke 1 (2.22) 14 (0.54) 15 (0.57) 0.137
Re-hospitalization 14 (31.11) 467 (18.04) 481 (18.27) 0.025
Cardiac 9 (64.29) 311 (67.90) 320 (67.80)
Non-cardiac 5 (35.71) 144 (31.44) 149 (31.57)
Both 0 (0.00) 3 (0.66) 3 (0.64)
Unknown 0 9 9
Repeat revascularization 1 (2.22) 55 (2.13) 56 (2.13) 0.965
6-month follow-up
Death 12 (25.53) 117 (4.65) 129 (5.03) \0.01
Myocardial Infarction 2 (5.13) 59 (2.44) 61 (2.48) 0.284
Stroke 1 (2.63) 24 (0.99) 25 (1.02) 0.318
Re-hospitalization 20 (47.62) 708 (28.51) 728 (28.83) \0.01
Cardiac 13 (65.00) 483 (69.20) 496 (69.08)
Non-cardiac 7 (35.00) 192 (27.51) 199 (27.72)
Both 0 (0.00) 23 (3.30) 23 (3.20)
Unknown 0 10 10
Repeat revascularization 2 (5.26) 89 (3.68) 91 (3.71) 0.609
9-month follow-up
Death 13 (28.26) 135 (5.55) 148 (5.97) \0.01
Myocardial Infarction 2 (5.71) 76 (3.28) 78 (3.32) 0.425
Stroke 1 (3.03) 30 (1.30) 31 (1.32) 0.387
Re-hospitalization 21 (51.22) 906 (37.59) 927 (37.82) 0.074
Cardiac 14 (66.67) 619 (69.08) 633 (69.03)
Non-cardiac 6 (28.57) 217 (24.22) 223 (24.32)
Both 1 (4.76) 60 (6.70) 61 (6.65)
Unknown 0 10 10
Repeat revascularization 4 (12.12) 128 (5.54) 132 (5.64) 0.104
12-month follow-up
Death 15 (31.91) 156 (6.54) 171 (7.03) \0.01
Myocardial Infarction 2 (5.71) 85 (3.77) 87 (3.80) 0.550
Stroke 1 (3.03) 34 (1.51) 35 (1.53) 0.481
Re-hospitalization 22 (52.38) 1011 (42.50) 1033 (42.67) 0.199
Cardiac 14 (63.64) 675 (67.43) 689 (67.35)
Non-cardiac 7 (31.82) 236 (23.58) 243 (23.75)
Both 1 (4.55) 90 (8.99) 91 (8.90)
Unknown 0 10 10
Repeat revascularization 4 (11.76) 156 (6.94) 160 (7.01) 0.274
446 Heart Vessels (2015) 30:441–450
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Several factors have been reported with IHB such as
age, female sex, use of anticoagulation and antiplatelet
agents. Different bleeding scores were also developed to
calculate the risk of IHB. Mehran et al. used 6 baseline
predictors (female sex, age, serum creatinine and white
blood cell count, anemia, non-ST-segment elevation MI or
ST-segment elevation MI) and 1 treatment-related variable
(use of heparin ? a glycoprotein IIb/IIIa inhibitor rather
than bivalirudin alone) to develop a risk score with c-sta-
tistic value 0.74. Similar to the GUSTO IV-ACS study, our
study found IHB were related with glycoprotein IIb/IIIa
inhibitor administration. Because there was no definite
cardiovascular benefit with adding glycoprotein IIb/IIIa to
the standard treatment regimen in Taiwan, we used gly-
coprotein IIb/IIIa inhibitor limited to the very high car-
diovascular risk population [19, 20]. Our study also found
that higher Killip class was related to IHB. The association
might just reflect the disease severity and co-morbidity.
In-hospital bleeding is associated with short-, interme-
diate-, and long-term mortality among patients hospitalized
Table 4 Multivariable-adjusted odds ratios for the association between in-hospital bleeding and 12 months cardiovascular events
Outcome/hazard ratio (95 % CI) Unadjusted Model I Model II Model III
Primary outcome
Overall cohort 3.66(2.18–6.17)* 2.85(1.69–4.81)* 1.57(0.91–2.70) 1.42(0.79–2.58)
STEMI 2.88(1.35–6.18)* 2.25(1.05–4.84)* 0.98(0.44–2.18) 0.96(0.42–2.17)
NSTE-ACS 5.36(2.62–10.95)* 3.82(1.87–7.83)* 2.74(1.29–5.84)* 2.34(0.94–5.86)
Secondary outcome
Overall cohort 1.74(1.19–2.53)* 1.63(1.12–2.37)* 1.43(0.97–2.10) 1.17(0.75–1.81)
STEMI subpopulation 1.35(0.81–2.25) 1.27(0.76–2.12) 1.16(0.69–1.97) 1.02(0.58–1.80)
NSTE-ACS 2.58(1.49–4.49)* 2.33(1.344.05)* 1.95(1.10–3.45)* 1.46(0.73–2.92)
Model 1: adjusted for age and sex. Model 2: adjusted for Model 1 covariates ? medicine at discharge (aspirin, clopidogrel, angiotensin-
converting enzyme inhibitor, angiotensin II receptor blocker, beta-blocker and statin). Model 3: adjusted for Model 2 covariates ? creatinine,
weight and Killip class
* p\ 0.05
Fig. 1 Kaplan–Meier curve analysis for in-hospital TIMI bleeding
and CKD on the a primary and b secondary end points among the
whole populations. TIMI thrombolysis in myocardial infarction, CKD
chronic kidney disease, ACS acute coronary syndrome






(n = 274) (%)
Primary end
point (-)






101 (36.86) 1745 (68.57) 1 –
IHB(?)/CKD
(-)
5 (1.82) 19 (0.75) 1.88(0.68–5.21) 0.227
IHB(-)/CKD
(?)
157 (57.30) 763 (29.98) 2.13(1.62–2.79) \0.01
IHB(?)/CKD
(?)
11 (4.01) 18 (0.71) 2.98(1.55–5.75) \0.01
IHB in-hospital bleeding, CKD chronic kidney disease
a Adjusted for age, sex and medicine at discharge (aspirin, clopidogrel,
angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, beta-
blocker and statin)
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for ACS and PCI [3, 4, 21]. Patients with IHB after primary
PCI in STE-ACS have significantly increased 3-year rates
of morbidity and mortality [22]. The deleterious effect of
major bleeding was observed within 1 month, between
1 month and 1 year, and between 1 and 3 years. In patients
with NSTE-ACS cumulative mortality was also higher in
those who had bleeding vs those without at 30 days, 1 year
and 3 years [21]. In our study ACS patients with TIMI
bleeding had higher in-hospital and 1-year mortality.
Although its causal relationship with mortality is unclear,
IHB likely identifies patients with an underlying risk for
mortality.
Taiwan has been recognized as an endemic area of
kidney disease with the highest incidence and prevalence
rates of ESRD in the world [9]. Because patients with CKD
have more comorbidity, their treatment strategy in ACS is
more complicated in the CKD endemic area. As shown in
our study CKD is a poor prognosis factor for those with
ACS, possibly because of more extensive and severe ath-
erosclerosis coronary tree with plaque composed of greater
necrotic core and less fibrous tissue in the CKD than non-
CKD subjects [23–25]. Furthermore, poor antiplatelet
responsiveness, underuse of reperfusion therapy, fear of
contrast-induced nephropathy during coronary procedure
and fewer guideline-recommended treatments prescribed
may partly explain why the CKD population had poor
prognosis in ACS [26–28].
Renal function impairment is associated with platelet
dysfunction and coagulopathy and therefore plays an
important role in the risk of bleeding. Creatinine only can
be integrated as one risk factor in a clinical score which
could identify patients at increased risk for bleeding and
subsequent 1-year mortality [29]. Estimated GFR and CKD
stages were also related to in-hospital bleeding, cardio-
vascular events and death [30, 31]. Bleeding itself might
further cause renal function deterioration and therefore a
vicious cycle develops. In this study we first found in-
hospital bleeding and CKD might have additively detri-
mental effect on the cardiovascular outcome. Strategies,
such as transradial approach, use of appropriate anticoag-
ulation, antiplatelet therapy and selected use of glycopro-
tein IIb/IIIa in the high-risk population, to reduce CKD and
bleeding are mandatory to reduce subsequent cardiovas-
cular events [32–34].
This study has six main limitations. Firstly, it is a non-
randomized and observational study. Nonetheless, this
study provides valuable real-world data on the current
practices across the full spectrum of ACS in a CKD
endemic area, which could help to improve the ACS
management in the CKD population. Second, the mecha-
nism why in-hospital bleeding and CKD have additively
detrimental effect of the cardiovascular outcome is unclear.
The casual relationship and which one happened first are
unknown. Third, the renal end point is not routinely col-
lected after discharge in this registry. Whether those with
TIMI bleeding had poor renal outcome is unknown. Fourth,
the renal parameter was incorporated into the CRUSADE
bleeding risk score, which might be a better score to define
bleeding risk. However, we cannot calculate the CRU-
SADE score because hematocrit was not collected in this
registry. Fifth, the prognostic difference between the in-
hospital hemoglobin changes and TIMI IHB might provide
different insight in clinical judgment. However, serial
hemoglobin data were not collected during admission in
this registry. Sixth, because the interaction test between
ACS type and bleeding on outcomes is non-significant, the
finding of excess risk in NSTE-ACS was only hypothesis
generating.
Conclusion
In this real-world registry, we found that patients with IHB
had higher risk of in-hospital and 12 months death in the
ACS population. Furthermore, patients with both IHB and
CKD had the worst prognosis during the 12 months follow-
up. Thus, all measures decreasing IHB and preventing
CKD in ACS patients are important for eventual cardio-
vascular risk reduction.
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